• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一例前列腺特异性抗原(PSA)水平较低的高级别前列腺癌病例。

A case of high-grade prostate cancer with low PSA levels.

作者信息

Bociański Jan, Sklinda Katarzyna, Walecki Jerzy, Rogowski Wojciech, Małek Michał, Kasprowicz Marek, Michałowski Łukasz, Popow Weronika

机构信息

Center of Radiological Diagnostics, The National Medical Institute of the Ministry of Interior and Administration, Wołoska 137, 02-507, Warsaw, Poland.

Clinical Department of Urology and Oncological Urology, The National Medical Institute of the Ministry of Interior and Administration, Wołoska 137, 02-507, Warsaw, Poland.

出版信息

Urol Case Rep. 2025 Aug 16;62:103161. doi: 10.1016/j.eucr.2025.103161. eCollection 2025 Sep.

DOI:10.1016/j.eucr.2025.103161
PMID:40894095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12398209/
Abstract

Prostate-specific antigen (PSA) levels typically correlate with the risk of prostate cancer. However, it is uncommon for an extensive malignant infiltration to occur with persistently low PSA levels. We present a case of a young male with a large tumor originating from the transition zone of the prostate and with low PSA levels This case underscores the biological heterogeneity of prostate cancer and suggests that tumors arising in the transition zone may differ significantly in behavior from those originating in the peripheral zone.

摘要

前列腺特异性抗原(PSA)水平通常与前列腺癌风险相关。然而,PSA水平持续较低时发生广泛恶性浸润的情况并不常见。我们报告一例年轻男性病例,其肿瘤较大,起源于前列腺移行带,且PSA水平较低。该病例强调了前列腺癌的生物学异质性,并表明起源于移行带的肿瘤在行为上可能与起源于外周带的肿瘤有显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/a43f0e5d4eac/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/a12ddf6177fd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/3e030b6865a1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/69c44325b3a0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/a43f0e5d4eac/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/a12ddf6177fd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/3e030b6865a1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/69c44325b3a0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b903/12398209/a43f0e5d4eac/gr4.jpg

相似文献

1
A case of high-grade prostate cancer with low PSA levels.一例前列腺特异性抗原(PSA)水平较低的高级别前列腺癌病例。
Urol Case Rep. 2025 Aug 16;62:103161. doi: 10.1016/j.eucr.2025.103161. eCollection 2025 Sep.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.前列腺癌筛查用 PSA、激肽释放酶组和 MRI:ProScreen 随机试验。
JAMA. 2024 May 7;331(17):1452-1459. doi: 10.1001/jama.2024.3841.
4
[Diagnostic value of hematological parameters for prostate cancer in patients with gray-zone prostate-specific antigen levels].[血液学参数对前列腺特异性抗原水平处于灰色地带的前列腺癌患者的诊断价值]
Zhonghua Nan Ke Xue. 2024 Aug;30(8):701-708.
5
Screening for prostate cancer.前列腺癌筛查
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.
6
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
7
Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature.根治性前列腺切除术后前列腺特异性抗原持续升高的处理:文献系统评价。
Eur Urol Oncol. 2021 Apr;4(2):150-169. doi: 10.1016/j.euo.2021.01.001. Epub 2021 Feb 8.
8
Lycopene for the prevention of prostate cancer.番茄红素用于预防前列腺癌。
Cochrane Database Syst Rev. 2011 Nov 9;2011(11):CD008007. doi: 10.1002/14651858.CD008007.pub2.
9
A deep learning derived prostate zonal volume-based biomarker from T2-weighted MRI to distinguish between prostate cancer and benign prostatic hyperplasia.一种基于深度学习从T2加权磁共振成像得出的前列腺带区体积生物标志物,用于区分前列腺癌和良性前列腺增生。
Med Phys. 2025 Aug;52(8):e18053. doi: 10.1002/mp.18053.
10
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer.优化前列腺癌根治术后挽救性放疗的时机和同期激素治疗的应用。
Eur Urol Oncol. 2018 May;1(1):3-18. doi: 10.1016/j.euo.2018.02.008. Epub 2018 May 15.

本文引用的文献

1
American Cancer Society's report on the status of cancer disparities in the United States, 2023.美国癌症协会关于 2023 年美国癌症差异现状的报告。
CA Cancer J Clin. 2024 Mar-Apr;74(2):136-166. doi: 10.3322/caac.21812. Epub 2023 Nov 14.
2
Incidental detection of localized prostate cancer with low PSA by computed tomography scan: A report of two cases.计算机断层扫描偶然发现低前列腺特异性抗原水平的局限性前列腺癌:两例报告。
Clin Case Rep. 2022 Dec 15;10(12):e6736. doi: 10.1002/ccr3.6736. eCollection 2022 Dec.
3
Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations.
高级前列腺癌中有无 DNA 损伤修复突变的间变特征。
Clin Genitourin Cancer. 2021 Dec;19(6):e352-e359. doi: 10.1016/j.clgc.2021.05.005. Epub 2021 May 17.
4
What You Need to Know Before Reading Multiparametric MRI for Prostate Cancer.在阅读前列腺癌多参数 MRI 之前需要了解的内容。
AJR Am J Roentgenol. 2020 Jun;214(6):1211-1219. doi: 10.2214/AJR.19.22751. Epub 2020 Apr 7.
5
Lineage relationship between prostate adenocarcinoma and small cell carcinoma.前列腺腺癌和小细胞癌之间的谱系关系。
BMC Cancer. 2019 May 30;19(1):518. doi: 10.1186/s12885-019-5680-7.
6
Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.前列腺影像报告和数据系统第 2.1 版:前列腺影像报告和数据系统第 2 版 2019 年更新。
Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18.
7
PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.PI-RADS前列腺影像报告和数据系统:2015版,第2版
Eur Urol. 2016 Jan;69(1):16-40. doi: 10.1016/j.eururo.2015.08.052. Epub 2015 Oct 1.
8
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.前列腺癌筛查:美国预防服务工作组推荐声明。
Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.
9
Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer.使用基于患者特异性 MRI 的前列腺模具验证多参数 MRI 在前列腺癌定位中的应用。
Urology. 2012 Jan;79(1):233-9. doi: 10.1016/j.urology.2011.10.002.
10
Prostate cancers in men with low PSA levels--must we find them?PSA水平低的男性中的前列腺癌——我们必须找到它们吗?
N Engl J Med. 2004 May 27;350(22):2292-4. doi: 10.1056/NEJMe048003.